The Effects of GSK2586881 on the Responses to Acute Hypoxia and Exercise

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 03 Jul 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alunacedase alfa (Primary)
Indications Acute lung injury; Pulmonary arterial hypertension; Respiratory distress syndrome
Focus Therapeutic Use
Sponsors GlaxoSmithKline

Most Recent Events

25 Jan 2019 Status changed from recruiting to discontinued.
02 Oct 2018 Planned End Date changed from 3 May 2019 to 14 Jun 2019.
02 Oct 2018 Planned primary completion date changed from 3 May 2019 to 14 Jun 2019.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight